Sunday, April 27, 2025 2:29:13 PM
Mr. Researcher, you are correct. The number of authors does not mean anything. It is the quality of authors and their credentials that you look for.
For example, one of the 73 Co Authors is Dr. Walter he is the Chief of Neurosurgery at UR Medicine's Highland Hospital and a Professor of Neurosurgery and Oncology at the University of Rochester Medical Center. He obtained his medical degree and completed neurosurgical residency training at Johns Hopkins University and Hospital, where he also completed a National Cancer Institute sponsored fellowship in neuro-oncology. Following completion of residency training he served on the faculty at the University of Pittsburgh, where he was named director of adult neuro-oncology, and was recruited to the University of Rochester in 2007. Dr. Walter performs brain and spinal tumor surgeries at both Strong Memorial Hospital and Rochester General Hospital. He sees patients in clinic at Strong Memorial Hospital, Rochester General Hospital, and Clifton Springs Hospital, and has special expertise in image guided neurosurgery, radiosurgery, and complex spinal surgery for tumors. He runs an active clinical research program that is involved in evaluating experimental therapeutics for patients with brain and spinal cancer. He is particularly interested in developing therapies that not only extend survival, but that also improve the quality of life for people afflicted with these diseases. He runs a research laboratory at the University of Rochester that seeks to develop new targets for tumors.
University of Rochester Medical center was a trial site for DCVax-L. So if you think Dr. Walter would endorse a product that doesn’t work, you’re crazy. Now let’s compare your credentials to Mr. Walter’s. I look forward to your post.
For example, one of the 73 Co Authors is Dr. Walter he is the Chief of Neurosurgery at UR Medicine's Highland Hospital and a Professor of Neurosurgery and Oncology at the University of Rochester Medical Center. He obtained his medical degree and completed neurosurgical residency training at Johns Hopkins University and Hospital, where he also completed a National Cancer Institute sponsored fellowship in neuro-oncology. Following completion of residency training he served on the faculty at the University of Pittsburgh, where he was named director of adult neuro-oncology, and was recruited to the University of Rochester in 2007. Dr. Walter performs brain and spinal tumor surgeries at both Strong Memorial Hospital and Rochester General Hospital. He sees patients in clinic at Strong Memorial Hospital, Rochester General Hospital, and Clifton Springs Hospital, and has special expertise in image guided neurosurgery, radiosurgery, and complex spinal surgery for tumors. He runs an active clinical research program that is involved in evaluating experimental therapeutics for patients with brain and spinal cancer. He is particularly interested in developing therapies that not only extend survival, but that also improve the quality of life for people afflicted with these diseases. He runs a research laboratory at the University of Rochester that seeks to develop new targets for tumors.
University of Rochester Medical center was a trial site for DCVax-L. So if you think Dr. Walter would endorse a product that doesn’t work, you’re crazy. Now let’s compare your credentials to Mr. Walter’s. I look forward to your post.
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
